Communications Medicine (Mar 2022)
Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test
- Juan Pablo Hinestrosa,
- Razelle Kurzrock,
- Jean M. Lewis,
- Nicholas J. Schork,
- Gregor Schroeder,
- Ashish M. Kamat,
- Andrew M. Lowy,
- Ramez N. Eskander,
- Orlando Perrera,
- David Searson,
- Kiarash Rastegar,
- Jake R. Hughes,
- Victor Ortiz,
- Iryna Clark,
- Heath I. Balcer,
- Larry Arakelyan,
- Robert Turner,
- Paul R. Billings,
- Mark J. Adler,
- Scott M. Lippman,
- Rajaram Krishnan
Affiliations
- Juan Pablo Hinestrosa
- Biological Dynamics, Inc
- Razelle Kurzrock
- WIN Consortium for Personalized Cancer Therapy
- Jean M. Lewis
- Biological Dynamics, Inc
- Nicholas J. Schork
- The Translational Genomics Research Institute (TGen)
- Gregor Schroeder
- Biological Dynamics, Inc
- Ashish M. Kamat
- University of Texas MD Anderson Cancer Center, Department of Urology
- Andrew M. Lowy
- University of California San Diego, Moores Cancer Center
- Ramez N. Eskander
- University of California San Diego, Moores Cancer Center
- Orlando Perrera
- Biological Dynamics, Inc
- David Searson
- Biological Dynamics, Inc
- Kiarash Rastegar
- Biological Dynamics, Inc
- Jake R. Hughes
- Biological Dynamics, Inc
- Victor Ortiz
- Biological Dynamics, Inc
- Iryna Clark
- Biological Dynamics, Inc
- Heath I. Balcer
- Biological Dynamics, Inc
- Larry Arakelyan
- Biological Dynamics, Inc
- Robert Turner
- Biological Dynamics, Inc
- Paul R. Billings
- Biological Dynamics, Inc
- Mark J. Adler
- San Diego Cancer Research Institute
- Scott M. Lippman
- University of California San Diego, Moores Cancer Center
- Rajaram Krishnan
- Biological Dynamics, Inc
- DOI
- https://doi.org/10.1038/s43856-022-00088-6
- Journal volume & issue
-
Vol. 2,
no. 1
pp. 1 – 9
Abstract
Hinestrosa et al. describe the early-stage detection of cancer using biomarkers present in circulating extracellular vesicles purified via an alternating current electrokinetics platform. They show, in a case-control study, that 95.7% of pancreatic, 75.0% of ovarian and 43.8% of bladder stage I and II cancers can be detected.
